Integrating CYP2D6 and MATE1 activities in drug–drug interaction assessment: Insights from newly developed antidepressant drug ammoxetine

Journal of Pharmacology and Experimental Therapeutics · Published 2026-06-04 · DOI 10.1016/j.jpet.2026.104940

Authors (2)

Ruolan Chen, Nicola Ferri

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Chen, R., Ferri, N. (2026). Integrating CYP2D6 and MATE1 activities in drug–drug interaction assessment: Insights from newly developed antidepressant drug ammoxetine. Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/j.jpet.2026.104940

Related articles

• DSP-2342, a novel 5-hydroxytryptamine 2A/7 receptor antagonist, has therapeutic potential for behavioral and psychological symptoms of dementia · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Structure-based prediction of muscarinic M1/M3 receptor antagonist activity: Curated dataset and scaffold-aware evaluation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Improving drug delivery to mitigate cisplatin nephrotoxicity · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Striatal remodeling in Parkinson disease · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Preclinical pharmacology of N-pyrrolidino “nitazene” opioids appearing in nonmedical drug markets · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Modulation of morphine tolerance and dependence by pyrroloquinoline quinone in mice: Insights into mechanistic bridge from N-methyl-D-aspartate receptors-calcium/calmodulin-dependent protein kinase II signaling to oxidative neuroinflammation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Comparative analysis of ligand binding affinities and functional profiles at recombinant human β-adrenergic receptor subtypes 1, 2, and 3 · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• An antidote in arms: A monoclonal antibody intervention to reverse fentanyl-induced respiratory apnea · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Chemotype-Dependent Dissociation of Binding Affinity and Functional Potency in Synthetic Cannabinoids · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal